source
- Regeneron defends M&A stance as cash hoard reaches $18 billion amid trial setbacksAnalysts on Regeneron's second‑quarter earnings call questioned the company's lack of merger and acquisition activity, pointing to an $18 billion cash reserve and recent clinical trial setbacks. C…
- Sanofi CEO pledges deeper review of late-stage pipeline before Phase 3 movesSanofi's new chief executive, Belén Garijo, announced that the company will examine its late-stage pipeline more closely. The goal is to ensure that data from Phase 2 (or Phase 1b, depending on th…